High Risk Neuroblastoma
specificNeuroblastoma usually presenting with metastatic disease and MYCN gene amplifications.
41
Centers
48
Active Trials
$569K
Cancer Funding
Top Centers for High Risk Neuroblastoma(41)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive High-Volume Research Center | 72.7 |
| 2 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive High-Volume Research Center | 71.1 |
| 3 | Boston University Cancer CenterBoston, MA High-Volume Research Center | 71.1 |
| 4 | Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 68.9 |
| 5 | University of Illinois Cancer CenterChicago, IL Active Research Program | 68.9 |
| 6 | NCI Comprehensive Active Research Program | 49.1 |
| 7 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 49.1 |
| 8 | UPMC Hillman Cancer CenterPittsburgh, PA NCI Comprehensive Active Research Program | 49.1 |
| 9 | Yale Cancer Center Yale School of MedicineNew Haven, CT NCI Comprehensive Active Research Program | 49.1 |
| 10 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive Active Research Program | 49.1 |
| 11 | NCI Comprehensive Active Research Program | 49.1 |
| 12 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 49.1 |
| 13 | NCI Comprehensive Active Research Program | 49.1 |
| 14 | NCI Comprehensive Active Research Program | 49.1 |
| 15 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive Active Research Program | 49.1 |
| 16 | Masonic Cancer CenterMinneapolis, MN NCI Comprehensive Active Research Program | 49.1 |
| 17 | NCI Comprehensive Active Research Program | 49.1 |
| 18 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 49.1 |
| 19 | Roswell Park Comprehensive Cancer CenterBuffalo, NY NCI Comprehensive Active Research Program | 49.1 |
| 20 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive Active Research Program | 49.1 |
| 21 | NCI Clinical Active Research Program | 49.1 |
| 22 | Medical College of Wisconsin Cancer CenterMilwaukee, WI Active Research Program | 49.1 |
| 23 | Cedars-Sinai CancerLos Angeles, CA Active Research Program | 49.1 |
| 24 | Cleveland Clinic Cancer CenterCleveland, OH Active Research Program | 49.1 |
| 25 | Holden Comprehensive Cancer CenterIowa City, IA NCI Comprehensive Active Research Program | 49.1 |
| 26 | Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical Active Research Program | 49.1 |
| 27 | Sidney Kimmel Comprehensive Cancer Center at JeffersonPhiladelphia, PA NCI Comprehensive Active Research Program | 49.1 |
| 28 | University of Hawai‘i Cancer CenterHonolulu, HI NCI Clinical Active Research Program | 49.1 |
| 29 | UAMS Winthrop P. Rockefeller Cancer InstituteLittle Rock, AR Active Research Program | 49.1 |
| 30 | Karmanos Cancer InstituteDetroit, MI NCI Comprehensive Active Research Program | 49.1 |
| 31 | Active Research Program | 49.1 |
| 32 | Cancer Center at IllinoisUrbana, IL Active Research Program | 49.1 |
| 33 | Penn State Cancer InstituteHershey, PA Active Research Program | 49.1 |
| 34 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 49.1 |
| 35 | Livestrong Cancer InstitutesAustin, TX Active Research Program | 49.1 |
| 36 | The University of Vermont Cancer CenterBurlington, VT Active Research Program | 49.1 |
| 37 | Active Research Program | 49.1 |
| 38 | Upstate Cancer CenterSyracuse, NY Active Research Program | 49.1 |
| 39 | Louisiana Cancer Research CenterNew Orleans, LA Active Research Program | 49.1 |
| 40 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 46.9 |
| 41 | BC CancerVancouver, BC | 29.4 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →